• 1
    Busch M, Chamberland M, Epstein J, Kleinman S, Khabbaz R, Nemo G. Oversight and monitoring of blood safety in the United States. Vox Sang 1999; 77: 6776.
  • 2
    Klein HG. Will blood transfusion ever be safe enough? JAMA 2000; 284: 23840.
  • 3
    Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 9759.
  • 4
    Pillonel J, Laperche S. Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing). Transfus Clin Biol 2004; 11: 816.
  • 5
    Schmidt PJ. Syphilis, a disease of direct transfusion. Transfusion 2001; 41: 106971.
  • 6
    Brecher ME, Hay SN, Rothenberg SJ. Monitoring of apheresis platelet bacterial contamination with an automated liquid culture system: a university experience. Transfusion 2003; 43: 9748.
  • 7
    Brecher ME, Hay SN. Improving platelet safety: bacterial contamination of platelets. Curr Hematol Rep 2004; 3: 1217.
  • 8
    Cable RG, Leiby DA. Risk and prevention of transfusion-transmitted babesiosis and other tick-borne diseases. Curr Opin Hematol 2003; 10: 40511.
  • 9
    Pealer LN, Marfin AA, Petersen LR et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003; 349: 123645.
  • 10
    Sarkodie F, Adarkwa M, Adu-Sarkodie Y, Candotti D, Acheampong JW, Allain JP. Screening for viral markers in volunteer and replacement blood donors in West Africa. Vox Sang 2001; 80: 1427.
  • 11
    Dhingra N, Lloyd SE, Fordham J, Amin NA. Challenges in global blood safety. World Hosp Health Serv 2004; 40: 459, 512.
  • 12
    Council of Europe. Pathogen inactivation of labile blood products. Transfus Med 2001; 11: 14975.
  • 13
    Kumar A, Kulkarni R, Murray DL et al. Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia. J Med Virol 1993; 41: 2059.
  • 14
    Skidmore SJ, Pasi KJ, Mawson SJ, Williams MD, Hill FG. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis. J Med Virol 1990; 30: 502.
  • 15
    Aledort LM, Levine PH, Hilgartner M et al. A study of liver biopsies and liver disease among hemophiliacs. Blood 1985; 66: 36772.
  • 16
    Evatt BL, Gomperts ED, McDougal JS, Ramsey RB. Coincidental appearance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Engl J Med 1985; 312: 4836.
  • 17
    Kroner BL, Rosenberg PS, Aledort LM, Alvord WG, Goedert JJ. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978–1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1994; 7: 27986.
  • 18
    Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39: 11608.
  • 19
    Kingdon HS, Lundblad RL. An adventure in biotechnology: the development of haemophilia A therapeutics – from whole-blood transfusion to recombinant DNA to gene therapy. Biotechnol Appl Biochem 2002; 35: 1418.
  • 20
    Mannucci PM, Colombo M, Rodeghiero F. Non-A, non-B hepatitis after factor VIII concentrate treated by heating and chloroform. Lancet 1985; 2: 1013.
  • 21
    Mariani G, Ghirardini A, Mandelli F et al. Heated clotting factors and seroconversion for human immunodeficiency virus in three hemophilic patients. Ann Intern Med 1987; 107: 113.
  • 22
    Mannucci PM, Schimpf K, Abe T et al. Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator Group. Transfusion 1992; 32: 1348.
  • 23
    Schulman S, Lindgren AC, Petrini P, Allander T. Transmission of hepatitis C with pasteurised factor VIII. Lancet 1992; 340: 3056.
  • 24
    Azzi A, Ciappi S, Zakvrzewska K, Morfini M, Mariani G, Mannucci PM. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol 1992; 39: 22830.
  • 25
    Rubinstein AI, Rubinstein DB. Inability of solvent-detergent (S-D) treated factor VIII concentrate to inactivate parvoviruses and non-lipid enveloped non-A, non-B hepatitis virus in factor VIII concentrate: advantages to using sterilizing 100 degrees C dry heat treatment. Am J Hematol 1990; 35: 142.
  • 26
    Prince AM, Horowitz B, Brotman B. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet 1986; 1: 70610.
  • 27
    Klein HG, Dodd RY, Dzik WH et al. Current status of solvent/detergent-treated frozen plasma. Transfusion 1998; 38: 1027.
  • 28
    Mannucci PM, Chediak J, Hanna W et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99: 4506.
  • 29
    Williamson LM, Llewelyn CA, Fisher NC et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999; 39: 122734.
  • 30
    Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003; 121: 77885.
  • 31
    Burnouf T, Radosevich M. Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003; 9: 2437.
  • 32
    Yokoyama T, Murai K, Murozuka T et al. Removal of small non-enveloped viruses by nanofiltration. Vox Sang 2004; 86: 2259.
  • 33
    Wagner SJ. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev 2002; 16: 616.
  • 34
    Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003; 43: 13229.
  • 35
    Bowden RA, Slichter SJ, Sayers M et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598603.
  • 36
    Brady MT, Milam JD, Anderson DC et al. Use of deglycerolized red blood cells to prevent posttransfusion infection with cytomegalovirus in neonates. J Infect Dis 1984; 150: 3349.
  • 37
    Sayers MH, Anderson KC, Goodnough LT et al. Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med 1992; 116: 5562.
  • 38
    Zucker-Franklin D, Seremetis S, Zheng ZY. Internalization of human immunodeficiency virus type I and other retroviruses by megakaryocytes and platelets. Blood 1990; 75: 19203.
  • 39
    Hess C, Klimkait T, Schlapbach L et al. Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study. Lancet 2002; 359: 22304.
  • 40
    Fast LD, Semple JW, DiLeone G et al. Inhibition of xenogeneic GVHD by PEN110 treatment of donor human PBMNCs. Transfusion 2004; 44: 2825.
  • 41
    Fast LD. The effect of exposing murine splenocytes to UVB light, psoralen plus UVA light, or gamma-irradiation on in vitro and in vivo immune responses. Transfusion 2003; 43: 57683.
  • 42
    Corash L. Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application. Transfus Apheresis Sci 2001; 25: 17981.
  • 43
    Corash L. Inactivation of infectious pathogens in labile blood components: meeting the challenge. Transfus Clin Biol 2001; 8: 13845.
  • 44
    Corash L. Pathogen reduction technology: methods, status of clinical trials, and future prospects. Curr Hematol Rep 2003; 2: 495502.
  • 45
    Purmal A, Valeri CR, Dzik W et al. Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies. Transfusion 2002; 42: 13945.
  • 46
    Lazo A, Tassello J, Jayarama V et al. Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry. Vox Sang 2002; 83: 31323.
  • 47
    Ohagen A, Gibaja V, Horrigan J et al. Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110. Vox Sang 2004; 87: 19.
  • 48
    Mather T, Takeda T, Tassello J et al. West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation. Transfusion 2003; 43: 102937.
  • 49
    Zavizion B, Pereira M, de Melo JM et al. Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry. Transfusion 2004; 44: 7318.
  • 50
    Zavizion B, Purmal A, Chapman J, Alford B. Inactivation of mycoplasma species in blood by INACTINE PEN110 process. Transfusion 2004; 44: 28693.
  • 51
    Zavizion B, Serebryanik D, Serebryanik I, Chapman J, Purmal A. Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process. Transfusion 2003; 43: 13542.
  • 52
    AuBuchon JP, Pickard CA, Herschel LH et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study. Transfusion 2002; 42: 14652.
  • 53
    Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000; 78(Suppl. 2): 2115.
  • 54
    McAteer M, Tay-Goodrich B, Doane S, Hansen E, McBurney LL, Stewart L. Photoinactivation of virus in packed red cell units using riboflavin and visible light. Transfusion 2000; 40(Suppl.): 37s.
  • 55
    Trannoy LL, Lagerberg JW, Dubbelman TM, Schuitmaker HJ, Brand A. Positively charged porphyrins: a new series of photosensitizers for sterilization of RBCs. Transfusion 2004; 44: 118696.
  • 56
    Hanson CV. Photochemical inactivation of viruses with psoralens: an overview. Blood Cells 1992; 18: 725.
  • 57
    Corash L, Lin L, Wiesehahn G. Use of 8-methoxypsoralen and long wavelength ultraviolet radiation for decontamination of platelet concentrates. Blood Cells 1992; 18: 5773.
  • 58
    Moroff G, Wagner S, Benade L, Dodd RY. Factors influencing virus inactivation and retention of platelet properties following treatment with aminomethyltrimethylpsoralen and ultraviolet A light. Blood Cells 1992; 18: 4354.
  • 59
    Goodrich RP, Yerram NR, Tay-Goodrich BH et al. Selective inactivation of viruses in the presence of human platelets: UV sensitization with psoralen derivatives. Proc Natl Acad Sci USA 1994; 91: 55526.
  • 60
    Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin Hematol 2001; 38(4 Suppl. 11): 411.
  • 61
    Ciaravi V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol 2001; 20: 53350.
  • 62
    van Rhenen DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000; 79: 20614.
  • 63
    Lin L, Dikeman R, Molini B et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004; 44: 1496504.
  • 64
    Corten L, Wiesenhahn J, Smyers KK, Murthy HM, Alter H. Photochemical inactivation of hepatitis B (HBV and hepatitis C (HCV) viruses in human plasma as assessed in a chimpanzee infectivity model. Blood 2000; 96: 60a.
  • 65
    McCullough J, Vesole DH, Benjamin RJ et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104: 153441.
  • 66
    Janetzko K, Lin L, Eichler H, Mayaudon V, Flament J, Kluter H. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004; 86: 23945.
  • 67
    Kumar V, Lockerbie O, Keil SD et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem Photobiol 2004; 80: 1521.
  • 68
    Dardare N, Platz MS. Binding affinities of commonly employed sensitizers of viral inactivation. Photochem Photobiol 2002; 75: 5614.
  • 69
    Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 87785.
  • 70
    FDA. Code of Federal Regulations. Vitamin B. 1998; CFR 21 Part 582.5695.
  • 71
    Hardwick CC, Herivel TR, Hernandez SC, Ruane PH, Goodrich RP. Separation, identification and quantification of riboflavin and its photoproducts in blood products using HPLC with fluorescence detection: a method to support pathogen reduction technology. Photochem Photobiol 2004; 80: 609615.
  • 72
    Li J, De Korte D, Woolum MD et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004; 87: 8290.
  • 73
    Hambleton J, Wages D, Radu-Radulescu L et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002; 42: 13027.
  • 74
    Mintz PD, Avery NL, Monlaison SL et al. Preparation of cryoprecipitate from photochemically treated fresh frozen plasma. Transfusion 2000; 40(Suppl.): 63s.
  • 75
    Von Fliedner VE, Jeannet M, Gratwohl A et al. Immunologic reactivity in marrow graft recipients receiving cyclosporine to prevent graft-versus-host disease. Transplantation 1983; 36: 12530.
  • 76
    Wagner FF, Flegel WA. Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes. Transfusion 1995; 35: 28491.
  • 77
    Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 1990; 323: 31521.
  • 78
    Williamson LM, Warwick RM. Transfusion-associated graft-versus-host disease and its prevention. Blood Rev 1995; 9: 25161.
  • 79
    Fast LD, DiLeone G, Edson CM, Purmal A. Inhibition of murine GVHD by PEN110 treatment. Transfusion 2002; 42: 132632.
  • 80
    Hearst JE, Reames A, Grass J, Talib S. S-59/UVA treated human T-cells with precisely controlled genomic addition frequencies retain immunological functions and yet are inhibited in proliferation. Blood 2001; 92(S1): 292b.